Alzamend Neuro, Inc. (ALZN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on March 29, 2024, by Alzamend Neuro, Inc., a Delaware corporation and emerging growth company. The report details a recent equity financing transaction and a critical regulatory notice regarding the company's listing status on The Nasdaq Capital Market.
Key Financial Metrics and Capital Structure
- Recent Financing: On March 26, 2024, the Company sold 780 shares of Series B Convertible Preferred Stock and warrants to purchase 780,000 shares of Common Stock to an affiliate, Ault Lending, LLC, for $780,000.
- Aggregate Funding: As of March 26, 2024, the Purchaser has acquired an aggregate of 2,000 shares of Series B Convertible Preferred Stock and warrants for 2,000,000 Warrant Shares, totaling $2.0 million in purchase price.
- Facility Capacity: The Securities Purchase Agreement allows the Purchaser to acquire up to $6 million in total Series B Convertible Preferred Stock and Warrants.
- Financial Statements: This filing does not provide revenue, profit, cash flow, margin, or debt metrics. The filing text does not provide a clear value for these operational financial indicators.
Material Changes and Listing Status
The Company failed to regain compliance with Nasdaq Listing Rule 5550(b)(2) regarding the Minimum Market Value of Listed Securities (MVLS). The MVLS remained below the required $35 million threshold for 30 consecutive trading days prior to the March 25, 2024 deadline.
- Delisting Notice: Nasdaq notified the Company on March 26, 2024, that it failed to meet the MVLS requirement.
- Proposed Action: Unless an appeal is successful, the Common Stock is scheduled for delisting and suspension of trading on April 4, 2024.
- Appeal Status: The Company intends to appeal the determination to a Hearings Panel by April 2, 2024. This appeal will stay the suspension and allow trading to continue pending the Panel's decision.
Outlook, Risks, and Contingencies
The primary risk identified is the potential delisting of the Company's Common Stock from The Nasdaq Capital Market. There is no assurance regarding the success of the appeal to the Hearings Panel. The Company continues to trade under the symbol "ALZN" while the appeal is pending. The financing transaction was conducted under Section 4(a)(2) of the Securities Act of 1933 as an unregistered sale to an affiliate.
Investor Verification Checklist
- Verify the outcome of the Nasdaq appeal hearing scheduled after April 2, 2024.
- Confirm the current Market Value of Listed Securities (MVLS) to assess compliance with the $35 million threshold.
- Review the terms of the Series B Convertible Preferred Stock and Warrants for dilution impact on existing shareholders.
- Monitor subsequent filings for updates on the $6 million financing facility and any additional closings.